Search
Now showing items 1-4 of 4
PD-L1 status in breast cancer: Current view and perspectives.
(
Elsevier
, 2019 , Article)
Breast cancer was traditionally not considered a particularly immunogenic tumor. However, recent developments have shown that some aggressive triple-negative breast cancers are immunogenic, exhibit a resistance to chemotherapy ...
Abstract B094: Novel method for patient stratification in breast carcinoma based upon spatial analysis of tumor microenvironment
(
American Association for Cancer Research
, 2019 , Conference Paper)
Breast cancer consists of several intrinsic molecular subtypes, providing the basis for clinical treatment decisions. Lately, it is becoming increasingly recognized that factors other than the intrinsic cancer characteristics, ...
Targeted immunotherapy with a checkpoint inhibitor in combination with chemotherapy: A new clinical paradigm in the treatment of triple-negative breast cancer.
(
Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
, 2019 , Article Review)
The treatment of several solid and hematologic malignancies with immune checkpoint inhibitors (against PD-1/PD-L1) has dramatically changed the cancer treatment paradigm. However, no checkpoint inhibitors were previously ...
Composition of the immune microenvironment differs between carcinomas metastatic to the lungs and primary lung carcinomas.
(
Elsevier
, 2018 , Article)
Lungs are among the most common sites for development of both primary and metastatic carcinomas. Tumor cells expression (TC) of PD-L1 is an important predictor of the of response to immune check-point inhibition in NSCLC, ...